Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort

We identified in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and pathological characteristics of the 10 index patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 2016-02, Vol.139 (Pt 2), p.452-467
Hauptverfasser: Van Mossevelde, Sara, van der Zee, Julie, Gijselinck, Ilse, Engelborghs, Sebastiaan, Sieben, Anne, Van Langenhove, Tim, De Bleecker, Jan, Baets, Jonathan, Vandenbulcke, Mathieu, Van Laere, Koen, Ceyssens, Sarah, Van den Broeck, Marleen, Peeters, Karin, Mattheijssens, Maria, Cras, Patrick, Vandenberghe, Rik, De Jonghe, Peter, Martin, Jean-Jacques, De Deyn, Peter P, Cruts, Marc, Van Broeckhoven, Christine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 467
container_issue Pt 2
container_start_page 452
container_title Brain (London, England : 1878)
container_volume 139
creator Van Mossevelde, Sara
van der Zee, Julie
Gijselinck, Ilse
Engelborghs, Sebastiaan
Sieben, Anne
Van Langenhove, Tim
De Bleecker, Jan
Baets, Jonathan
Vandenbulcke, Mathieu
Van Laere, Koen
Ceyssens, Sarah
Van den Broeck, Marleen
Peeters, Karin
Mattheijssens, Maria
Cras, Patrick
Vandenberghe, Rik
De Jonghe, Peter
Martin, Jean-Jacques
De Deyn, Peter P
Cruts, Marc
Van Broeckhoven, Christine
description We identified in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and pathological characteristics of the 10 index patients and six of their affected relatives carrying a TBK1 mutation. Six TBK1 carriers were diagnosed with frontotemporal dementia, seven with amyotrophic lateral sclerosis, one with both clinical phenotypes and two with dementia unspecified. The mean age at onset of all 16 TBK1 carriers was 62.1 ± 8.9 years (range 41-73) with a mean disease duration of 4.7 ± 4.5 years (range 1-13). TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than carriers with frontotemporal dementia. Six of seven TBK1 carriers were diagnosed with the behavioural variant of frontotemporal dementia, presenting predominantly as disinhibition. Memory loss was an important associated symptom in the initial phase of the disease in all but one of the carriers with frontotemporal dementia. Three of the patients with amyotrophic lateral sclerosis exhibited pronounced upper motor neuron symptoms. Overall, neuroimaging displayed widespread atrophy, both symmetric and asymmetric. Brain perfusion single-photon emission computed tomography or fluorodeoxyglucose-positron emission tomography showed asymmetric and predominantly frontotemporal involvement. Neuropathology in two patients demonstrated TDP-43 type B pathology. Further, we compared genotype-phenotype data of TBK1 carriers with frontotemporal dementia (n = 7), with those of frontotemporal dementia patients with a C9orf72 repeat expansion (n = 65) or a GRN mutation (n = 52) and with frontotemporal dementia patients (n = 259) negative for mutations in currently known causal genes. TBK1 carriers with frontotemporal dementia had a later age at onset (63.3 years) than C9orf72 carriers (54.3 years) (P = 0.019). In clear contrast with TBK1 carriers, GRN carriers were more often diagnosed with the language variant than the behavioural variant, and presented in case of the diagnosis of behavioural variant, more often than TBK1 carriers with apathy as the predominant characteristic (P = 0.004). Also, TBK1 carriers exhibited more often extrapyramidal symptoms than C9orf72 carriers (P = 0.038). In conclusion, our study identified clinical differences between the TBK1, C9orf72 and GRN carriers, which allows us to formulate guideline
doi_str_mv 10.1093/brain/awv358
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4805085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1768565639</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-59e158095c264dfada080ec91242b84124ea0b5162df6bc3f443b3c6ead7b46b3</originalsourceid><addsrcrecordid>eNpVkU1PwzAMhiMEgjG4cUY5cqCQNB9rL0gwwUAgkBCcIzdNt0CbjKTdxL-nMBhwsmQ_fm3pQeiAkhNKcnZaBLDuFJYLJrINNKBckiSlQm6iASFEJlkuyA7ajfGFEMpZKrfRTirliEshBuh1XFtnNdS4MtB2wUTsK_x0cUuxhhCsCRFr38whmBIvbTvD49yHapQe48njPQZXYudd0nQttNa73yXrMOALU08t9F0_86HdQ1sV1NHsf9cher66fBpfJ3cPk5vx-V2iOZVtInJDRUZyoVPJywpKIBkxOqcpT4uM98UAKQSVaVnJQrOKc1YwLQ2Uo4LLgg3R2Sp33hWNKbVxbYBazYNtILwrD1b9nzg7U1O_UDwjgmSiDzj6Dgj-rTOxVY2N2tQ1OOO7qOhIZkIKyfIePV6hOvgYg6nWZyhRn37Ulx-18tPjh39fW8M_QtgHYPuOYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768565639</pqid></control><display><type>article</type><title>Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Van Mossevelde, Sara ; van der Zee, Julie ; Gijselinck, Ilse ; Engelborghs, Sebastiaan ; Sieben, Anne ; Van Langenhove, Tim ; De Bleecker, Jan ; Baets, Jonathan ; Vandenbulcke, Mathieu ; Van Laere, Koen ; Ceyssens, Sarah ; Van den Broeck, Marleen ; Peeters, Karin ; Mattheijssens, Maria ; Cras, Patrick ; Vandenberghe, Rik ; De Jonghe, Peter ; Martin, Jean-Jacques ; De Deyn, Peter P ; Cruts, Marc ; Van Broeckhoven, Christine</creator><creatorcontrib>Van Mossevelde, Sara ; van der Zee, Julie ; Gijselinck, Ilse ; Engelborghs, Sebastiaan ; Sieben, Anne ; Van Langenhove, Tim ; De Bleecker, Jan ; Baets, Jonathan ; Vandenbulcke, Mathieu ; Van Laere, Koen ; Ceyssens, Sarah ; Van den Broeck, Marleen ; Peeters, Karin ; Mattheijssens, Maria ; Cras, Patrick ; Vandenberghe, Rik ; De Jonghe, Peter ; Martin, Jean-Jacques ; De Deyn, Peter P ; Cruts, Marc ; Van Broeckhoven, Christine ; Belgian Neurology consortium</creatorcontrib><description>We identified in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and pathological characteristics of the 10 index patients and six of their affected relatives carrying a TBK1 mutation. Six TBK1 carriers were diagnosed with frontotemporal dementia, seven with amyotrophic lateral sclerosis, one with both clinical phenotypes and two with dementia unspecified. The mean age at onset of all 16 TBK1 carriers was 62.1 ± 8.9 years (range 41-73) with a mean disease duration of 4.7 ± 4.5 years (range 1-13). TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than carriers with frontotemporal dementia. Six of seven TBK1 carriers were diagnosed with the behavioural variant of frontotemporal dementia, presenting predominantly as disinhibition. Memory loss was an important associated symptom in the initial phase of the disease in all but one of the carriers with frontotemporal dementia. Three of the patients with amyotrophic lateral sclerosis exhibited pronounced upper motor neuron symptoms. Overall, neuroimaging displayed widespread atrophy, both symmetric and asymmetric. Brain perfusion single-photon emission computed tomography or fluorodeoxyglucose-positron emission tomography showed asymmetric and predominantly frontotemporal involvement. Neuropathology in two patients demonstrated TDP-43 type B pathology. Further, we compared genotype-phenotype data of TBK1 carriers with frontotemporal dementia (n = 7), with those of frontotemporal dementia patients with a C9orf72 repeat expansion (n = 65) or a GRN mutation (n = 52) and with frontotemporal dementia patients (n = 259) negative for mutations in currently known causal genes. TBK1 carriers with frontotemporal dementia had a later age at onset (63.3 years) than C9orf72 carriers (54.3 years) (P = 0.019). In clear contrast with TBK1 carriers, GRN carriers were more often diagnosed with the language variant than the behavioural variant, and presented in case of the diagnosis of behavioural variant, more often than TBK1 carriers with apathy as the predominant characteristic (P = 0.004). Also, TBK1 carriers exhibited more often extrapyramidal symptoms than C9orf72 carriers (P = 0.038). In conclusion, our study identified clinical differences between the TBK1, C9orf72 and GRN carriers, which allows us to formulate guidelines for genetic diagnosis. After a negative result for C9orf72, patients with both frontotemporal dementia and amyotrophic lateral sclerosis should be tested first for mutations in TBK1. Specifically in frontotemporal dementia patients with early memory difficulties, a relatively late age at onset or extrapyramidal symptoms, screening for TBK1 mutations should be considered.</description><identifier>ISSN: 0006-8950</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awv358</identifier><identifier>PMID: 26674655</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Aged ; Amyotrophic Lateral Sclerosis - diagnosis ; Amyotrophic Lateral Sclerosis - epidemiology ; Amyotrophic Lateral Sclerosis - genetics ; Belgium - epidemiology ; C9orf72 Protein ; Cohort Studies ; Female ; Frontotemporal Dementia - diagnosis ; Frontotemporal Dementia - epidemiology ; Frontotemporal Dementia - genetics ; Heterozygote ; Humans ; Intercellular Signaling Peptides and Proteins - genetics ; Male ; Middle Aged ; Mutation - genetics ; Original ; Pedigree ; Protein-Serine-Threonine Kinases - genetics ; Proteins - genetics</subject><ispartof>Brain (London, England : 1878), 2016-02, Vol.139 (Pt 2), p.452-467</ispartof><rights>The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain.</rights><rights>The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-59e158095c264dfada080ec91242b84124ea0b5162df6bc3f443b3c6ead7b46b3</citedby><cites>FETCH-LOGICAL-c416t-59e158095c264dfada080ec91242b84124ea0b5162df6bc3f443b3c6ead7b46b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26674655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Mossevelde, Sara</creatorcontrib><creatorcontrib>van der Zee, Julie</creatorcontrib><creatorcontrib>Gijselinck, Ilse</creatorcontrib><creatorcontrib>Engelborghs, Sebastiaan</creatorcontrib><creatorcontrib>Sieben, Anne</creatorcontrib><creatorcontrib>Van Langenhove, Tim</creatorcontrib><creatorcontrib>De Bleecker, Jan</creatorcontrib><creatorcontrib>Baets, Jonathan</creatorcontrib><creatorcontrib>Vandenbulcke, Mathieu</creatorcontrib><creatorcontrib>Van Laere, Koen</creatorcontrib><creatorcontrib>Ceyssens, Sarah</creatorcontrib><creatorcontrib>Van den Broeck, Marleen</creatorcontrib><creatorcontrib>Peeters, Karin</creatorcontrib><creatorcontrib>Mattheijssens, Maria</creatorcontrib><creatorcontrib>Cras, Patrick</creatorcontrib><creatorcontrib>Vandenberghe, Rik</creatorcontrib><creatorcontrib>De Jonghe, Peter</creatorcontrib><creatorcontrib>Martin, Jean-Jacques</creatorcontrib><creatorcontrib>De Deyn, Peter P</creatorcontrib><creatorcontrib>Cruts, Marc</creatorcontrib><creatorcontrib>Van Broeckhoven, Christine</creatorcontrib><creatorcontrib>Belgian Neurology consortium</creatorcontrib><title>Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>We identified in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and pathological characteristics of the 10 index patients and six of their affected relatives carrying a TBK1 mutation. Six TBK1 carriers were diagnosed with frontotemporal dementia, seven with amyotrophic lateral sclerosis, one with both clinical phenotypes and two with dementia unspecified. The mean age at onset of all 16 TBK1 carriers was 62.1 ± 8.9 years (range 41-73) with a mean disease duration of 4.7 ± 4.5 years (range 1-13). TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than carriers with frontotemporal dementia. Six of seven TBK1 carriers were diagnosed with the behavioural variant of frontotemporal dementia, presenting predominantly as disinhibition. Memory loss was an important associated symptom in the initial phase of the disease in all but one of the carriers with frontotemporal dementia. Three of the patients with amyotrophic lateral sclerosis exhibited pronounced upper motor neuron symptoms. Overall, neuroimaging displayed widespread atrophy, both symmetric and asymmetric. Brain perfusion single-photon emission computed tomography or fluorodeoxyglucose-positron emission tomography showed asymmetric and predominantly frontotemporal involvement. Neuropathology in two patients demonstrated TDP-43 type B pathology. Further, we compared genotype-phenotype data of TBK1 carriers with frontotemporal dementia (n = 7), with those of frontotemporal dementia patients with a C9orf72 repeat expansion (n = 65) or a GRN mutation (n = 52) and with frontotemporal dementia patients (n = 259) negative for mutations in currently known causal genes. TBK1 carriers with frontotemporal dementia had a later age at onset (63.3 years) than C9orf72 carriers (54.3 years) (P = 0.019). In clear contrast with TBK1 carriers, GRN carriers were more often diagnosed with the language variant than the behavioural variant, and presented in case of the diagnosis of behavioural variant, more often than TBK1 carriers with apathy as the predominant characteristic (P = 0.004). Also, TBK1 carriers exhibited more often extrapyramidal symptoms than C9orf72 carriers (P = 0.038). In conclusion, our study identified clinical differences between the TBK1, C9orf72 and GRN carriers, which allows us to formulate guidelines for genetic diagnosis. After a negative result for C9orf72, patients with both frontotemporal dementia and amyotrophic lateral sclerosis should be tested first for mutations in TBK1. Specifically in frontotemporal dementia patients with early memory difficulties, a relatively late age at onset or extrapyramidal symptoms, screening for TBK1 mutations should be considered.</description><subject>Adult</subject><subject>Aged</subject><subject>Amyotrophic Lateral Sclerosis - diagnosis</subject><subject>Amyotrophic Lateral Sclerosis - epidemiology</subject><subject>Amyotrophic Lateral Sclerosis - genetics</subject><subject>Belgium - epidemiology</subject><subject>C9orf72 Protein</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Frontotemporal Dementia - diagnosis</subject><subject>Frontotemporal Dementia - epidemiology</subject><subject>Frontotemporal Dementia - genetics</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Intercellular Signaling Peptides and Proteins - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation - genetics</subject><subject>Original</subject><subject>Pedigree</subject><subject>Protein-Serine-Threonine Kinases - genetics</subject><subject>Proteins - genetics</subject><issn>0006-8950</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1PwzAMhiMEgjG4cUY5cqCQNB9rL0gwwUAgkBCcIzdNt0CbjKTdxL-nMBhwsmQ_fm3pQeiAkhNKcnZaBLDuFJYLJrINNKBckiSlQm6iASFEJlkuyA7ajfGFEMpZKrfRTirliEshBuh1XFtnNdS4MtB2wUTsK_x0cUuxhhCsCRFr38whmBIvbTvD49yHapQe48njPQZXYudd0nQttNa73yXrMOALU08t9F0_86HdQ1sV1NHsf9cher66fBpfJ3cPk5vx-V2iOZVtInJDRUZyoVPJywpKIBkxOqcpT4uM98UAKQSVaVnJQrOKc1YwLQ2Uo4LLgg3R2Sp33hWNKbVxbYBazYNtILwrD1b9nzg7U1O_UDwjgmSiDzj6Dgj-rTOxVY2N2tQ1OOO7qOhIZkIKyfIePV6hOvgYg6nWZyhRn37Ulx-18tPjh39fW8M_QtgHYPuOYg</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Van Mossevelde, Sara</creator><creator>van der Zee, Julie</creator><creator>Gijselinck, Ilse</creator><creator>Engelborghs, Sebastiaan</creator><creator>Sieben, Anne</creator><creator>Van Langenhove, Tim</creator><creator>De Bleecker, Jan</creator><creator>Baets, Jonathan</creator><creator>Vandenbulcke, Mathieu</creator><creator>Van Laere, Koen</creator><creator>Ceyssens, Sarah</creator><creator>Van den Broeck, Marleen</creator><creator>Peeters, Karin</creator><creator>Mattheijssens, Maria</creator><creator>Cras, Patrick</creator><creator>Vandenberghe, Rik</creator><creator>De Jonghe, Peter</creator><creator>Martin, Jean-Jacques</creator><creator>De Deyn, Peter P</creator><creator>Cruts, Marc</creator><creator>Van Broeckhoven, Christine</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160201</creationdate><title>Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort</title><author>Van Mossevelde, Sara ; van der Zee, Julie ; Gijselinck, Ilse ; Engelborghs, Sebastiaan ; Sieben, Anne ; Van Langenhove, Tim ; De Bleecker, Jan ; Baets, Jonathan ; Vandenbulcke, Mathieu ; Van Laere, Koen ; Ceyssens, Sarah ; Van den Broeck, Marleen ; Peeters, Karin ; Mattheijssens, Maria ; Cras, Patrick ; Vandenberghe, Rik ; De Jonghe, Peter ; Martin, Jean-Jacques ; De Deyn, Peter P ; Cruts, Marc ; Van Broeckhoven, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-59e158095c264dfada080ec91242b84124ea0b5162df6bc3f443b3c6ead7b46b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amyotrophic Lateral Sclerosis - diagnosis</topic><topic>Amyotrophic Lateral Sclerosis - epidemiology</topic><topic>Amyotrophic Lateral Sclerosis - genetics</topic><topic>Belgium - epidemiology</topic><topic>C9orf72 Protein</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Frontotemporal Dementia - diagnosis</topic><topic>Frontotemporal Dementia - epidemiology</topic><topic>Frontotemporal Dementia - genetics</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Intercellular Signaling Peptides and Proteins - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation - genetics</topic><topic>Original</topic><topic>Pedigree</topic><topic>Protein-Serine-Threonine Kinases - genetics</topic><topic>Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Mossevelde, Sara</creatorcontrib><creatorcontrib>van der Zee, Julie</creatorcontrib><creatorcontrib>Gijselinck, Ilse</creatorcontrib><creatorcontrib>Engelborghs, Sebastiaan</creatorcontrib><creatorcontrib>Sieben, Anne</creatorcontrib><creatorcontrib>Van Langenhove, Tim</creatorcontrib><creatorcontrib>De Bleecker, Jan</creatorcontrib><creatorcontrib>Baets, Jonathan</creatorcontrib><creatorcontrib>Vandenbulcke, Mathieu</creatorcontrib><creatorcontrib>Van Laere, Koen</creatorcontrib><creatorcontrib>Ceyssens, Sarah</creatorcontrib><creatorcontrib>Van den Broeck, Marleen</creatorcontrib><creatorcontrib>Peeters, Karin</creatorcontrib><creatorcontrib>Mattheijssens, Maria</creatorcontrib><creatorcontrib>Cras, Patrick</creatorcontrib><creatorcontrib>Vandenberghe, Rik</creatorcontrib><creatorcontrib>De Jonghe, Peter</creatorcontrib><creatorcontrib>Martin, Jean-Jacques</creatorcontrib><creatorcontrib>De Deyn, Peter P</creatorcontrib><creatorcontrib>Cruts, Marc</creatorcontrib><creatorcontrib>Van Broeckhoven, Christine</creatorcontrib><creatorcontrib>Belgian Neurology consortium</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Mossevelde, Sara</au><au>van der Zee, Julie</au><au>Gijselinck, Ilse</au><au>Engelborghs, Sebastiaan</au><au>Sieben, Anne</au><au>Van Langenhove, Tim</au><au>De Bleecker, Jan</au><au>Baets, Jonathan</au><au>Vandenbulcke, Mathieu</au><au>Van Laere, Koen</au><au>Ceyssens, Sarah</au><au>Van den Broeck, Marleen</au><au>Peeters, Karin</au><au>Mattheijssens, Maria</au><au>Cras, Patrick</au><au>Vandenberghe, Rik</au><au>De Jonghe, Peter</au><au>Martin, Jean-Jacques</au><au>De Deyn, Peter P</au><au>Cruts, Marc</au><au>Van Broeckhoven, Christine</au><aucorp>Belgian Neurology consortium</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>139</volume><issue>Pt 2</issue><spage>452</spage><epage>467</epage><pages>452-467</pages><issn>0006-8950</issn><eissn>1460-2156</eissn><abstract>We identified in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and pathological characteristics of the 10 index patients and six of their affected relatives carrying a TBK1 mutation. Six TBK1 carriers were diagnosed with frontotemporal dementia, seven with amyotrophic lateral sclerosis, one with both clinical phenotypes and two with dementia unspecified. The mean age at onset of all 16 TBK1 carriers was 62.1 ± 8.9 years (range 41-73) with a mean disease duration of 4.7 ± 4.5 years (range 1-13). TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than carriers with frontotemporal dementia. Six of seven TBK1 carriers were diagnosed with the behavioural variant of frontotemporal dementia, presenting predominantly as disinhibition. Memory loss was an important associated symptom in the initial phase of the disease in all but one of the carriers with frontotemporal dementia. Three of the patients with amyotrophic lateral sclerosis exhibited pronounced upper motor neuron symptoms. Overall, neuroimaging displayed widespread atrophy, both symmetric and asymmetric. Brain perfusion single-photon emission computed tomography or fluorodeoxyglucose-positron emission tomography showed asymmetric and predominantly frontotemporal involvement. Neuropathology in two patients demonstrated TDP-43 type B pathology. Further, we compared genotype-phenotype data of TBK1 carriers with frontotemporal dementia (n = 7), with those of frontotemporal dementia patients with a C9orf72 repeat expansion (n = 65) or a GRN mutation (n = 52) and with frontotemporal dementia patients (n = 259) negative for mutations in currently known causal genes. TBK1 carriers with frontotemporal dementia had a later age at onset (63.3 years) than C9orf72 carriers (54.3 years) (P = 0.019). In clear contrast with TBK1 carriers, GRN carriers were more often diagnosed with the language variant than the behavioural variant, and presented in case of the diagnosis of behavioural variant, more often than TBK1 carriers with apathy as the predominant characteristic (P = 0.004). Also, TBK1 carriers exhibited more often extrapyramidal symptoms than C9orf72 carriers (P = 0.038). In conclusion, our study identified clinical differences between the TBK1, C9orf72 and GRN carriers, which allows us to formulate guidelines for genetic diagnosis. After a negative result for C9orf72, patients with both frontotemporal dementia and amyotrophic lateral sclerosis should be tested first for mutations in TBK1. Specifically in frontotemporal dementia patients with early memory difficulties, a relatively late age at onset or extrapyramidal symptoms, screening for TBK1 mutations should be considered.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>26674655</pmid><doi>10.1093/brain/awv358</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8950
ispartof Brain (London, England : 1878), 2016-02, Vol.139 (Pt 2), p.452-467
issn 0006-8950
1460-2156
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4805085
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Aged
Amyotrophic Lateral Sclerosis - diagnosis
Amyotrophic Lateral Sclerosis - epidemiology
Amyotrophic Lateral Sclerosis - genetics
Belgium - epidemiology
C9orf72 Protein
Cohort Studies
Female
Frontotemporal Dementia - diagnosis
Frontotemporal Dementia - epidemiology
Frontotemporal Dementia - genetics
Heterozygote
Humans
Intercellular Signaling Peptides and Proteins - genetics
Male
Middle Aged
Mutation - genetics
Original
Pedigree
Protein-Serine-Threonine Kinases - genetics
Proteins - genetics
title Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T14%3A17%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20features%20of%20TBK1%20carriers%20compared%20with%20C9orf72,%20GRN%20and%20non-mutation%20carriers%20in%20a%20Belgian%20cohort&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Van%20Mossevelde,%20Sara&rft.aucorp=Belgian%20Neurology%20consortium&rft.date=2016-02-01&rft.volume=139&rft.issue=Pt%202&rft.spage=452&rft.epage=467&rft.pages=452-467&rft.issn=0006-8950&rft.eissn=1460-2156&rft_id=info:doi/10.1093/brain/awv358&rft_dat=%3Cproquest_pubme%3E1768565639%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1768565639&rft_id=info:pmid/26674655&rfr_iscdi=true